MarketWatch

Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD

The MarketWatch News Department was not involved in the creation of this content. Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class ...
MarketWatch

32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics

The MarketWatch News Department was not involved in the creation of this content. Series A expected to advance lead asset Mucosal-Immune Modulator CS-0003 through Phase II in GI surgical site ...
Business Wire

32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics

NORTH CHICAGO, Ill.--(BUSINESS WIRE)--32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, today announced that ...
BioSpace

32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics

Series A expected to advance lead asset Mucosal-Immune Modulator CS-0003 through Phase II in GI surgical site infections and expand a differentiated GI mucosal-immune pipeline and metabolomics-driven ...
Joplin Globe

Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions

Poplar Therapeutics, Inc. announced its launch today highlighting its $50 million Series A financing led by SR One, Vida Ventures and Platanus. Previously known as Phylaxis Bioscience, Poplar ...
news.bloomberglaw

Kemper Sports Management Workers Advance Data Breach Class Suit

Golf-course management company Kemper Sports Management LLC must face a proposed class action alleging it negligently failed to protect the personal information of nearly 63,000 employees and former ...